CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
zeaxanthin +1 moredrug
Likely dose
zeaxanthin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01354093
NCT01354093N/ACompleted

Utah Center for the Collaborative Study of the Role of the Macular Pigment Carotenoids in the Pathogenesis and Treatment of MacTel

Paul S. Bernstein·observational·Posted May 16, 2011·Updated Jun 23, 2017

In Brief

An observational study evaluating zeaxanthin for Idiopathic Juxtafoveal Telangiectasia. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Macular telangiectasia type 2 ("MacTel Type 2") is an uncommon eye disorder that results in slow vision loss beginning in middle age. The macula is the central part of the retina, which lines the back of the eye like the film of a camera. The macula is responsible for central or reading vision. Telangiectasis refers to dilated, leaky vessels, for example varicose veins in the legs. One of the earliest manifestations of macular telangiectasia type 2 is an acquired reduction and/or redistribution of the macular pigment carotenoids at the foveal center. Currently, the biochemical mechanisms and clinical significance underlying these changes are not known, but it seems likely that better understanding of this phenomenon could lead to new interventions against MacTel. The objectives of this study are to image the maculas of MacTel subjects using two-wavelength autofluorescence imaging and resonance Raman imaging to target the 7-degree radius pigment ring characteristic of macular telangiectasia type 2 in order to gain further insight into the significance of this early clinical sign, and to evaluate whether supplementation with oral zeaxanthin can normalize macular pigment distribution in MacTel subjects

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 16, 2011
Enrollment StartNov 1, 2011
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 15.1 years ago

Interventions

zeaxanthindrug

10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day

zeaxanthindrug

10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day